ENTRY       D11082                      Drug
NAME        Anifrolumab (USAN);
            Anifrolumab (genetical recombination) (JAN);
            Anifrolumab-fnia;
            Saphnelo (TN)
PRODUCT     SAPHNELO (AstraZeneca Pharmaceuticals LP)
FORMULA     C6444H9964N1712O2018S44
EXACT_MASS  145027.7401
MOL_WEIGHT  145117.1846
SEQUENCE    (Heavy chain)
            EVQLVQSGAE VKKPGESLKI SCKGSGYIFT NYWIAWVRQM PGKGLESMGI IYPGDSDIRY
            SPSFQGQVTI SADKSITTAY LQWSSLKASD TAMYYCARHD IEGFDYWGRG TLVTVSSAST
            KGPSVFPLAP SSKSTSGGTA ALGCLVKDYF PEPVTVSWNS GALTSGVHTF PAVLQSSGLY
            SLSSVVTVPS SSLGTQTYIC NVNHKPSNTK VDKRVEPKSC DKTHTCPPCP APEFEGGPSV
            FLFPPKPKDT LMISRTPEVT CVVVDVSHED PEVKFNWYVD GVEVHNAKTK PREEQYNSTY
            RVVSVLTVLH QDWLNGKEYK CKVSNKALPA SIEKTISKAK GQPREPQVYT LPPSREEMTK
            NQVSLTCLVK GFYPSDIAVE WESNGQPENN YKTTPPVLDS DGSFFLYSKL TVDKSRWQQG
            NVFSCSVMHE ALHNHYTQKS LSLSPGK
            (Lihgt chain)
            EIVLTQSPGT LSLSPGERAT LSCRASQSVS SSFFAWYQQK PGQAPRLLIY GASSRATGIP
            DRLSGSGSGT DFTLTITRLE PEDFAVYYCQ QYDSSAITFG QGTRLEIKRT VAAPSVFIFP
            PSDEQLKSGT ASVVCLLNNF YPREAKVQWK VDNALQSGNS QESVTEQDSK DSTYSLSSTL
            TLSKADYEKH KVYACEVTHQ GLSSPVTKSF NRGEC
            (Disulfide bridge: H22-96, H144-H200, H220-L215, H226-H'226, H229-H'229, H261-H321, H367-H425, H'22-H'96, H'144-H'200, H'220-L'215, H'261-H'321, H'367-H'425, L23-L89, L135-L195, L'23-L'89, L'135-L'195)
  TYPE      Peptide
REMARK      Therapeutic category: 3999
            ATC code: L04AA51
            Product: D11082<JP/US>
EFFICACY    Immunomodulator, Anti-IFN-type 1 receptor antibody
  DISEASE   Systemic lupus erythematosus [DS:H00080]
  TYPE      Monoclonal antibody
COMMENT     Treatment of systemic lupus erythematosus (SLE)
TARGET      IFNAR1 [HSA:3454] [KO:K05130]
            IFNAR2 [HSA:3455] [KO:K05131]
  PATHWAY   hsa04060(3454+3455)  Cytokine-cytokine receptor interaction
INTERACTION  
BRITE       Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
             L ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
              L04 IMMUNOSUPPRESSANTS
               L04A IMMUNOSUPPRESSANTS
                L04AA Selective immunosuppressants
                 L04AA51 Anifrolumab
                  D11082  Anifrolumab (USAN) &lt;JP/US&gt;
            USP drug classification [BR:br08302]
             Immunological Agents
              Immunological Agents, Other
               Immunological Agents, Miscellaneous
                Anifrolumab
                 D11082  Anifrolumab (USAN)
            Therapeutic category of drugs in Japan [BR:br08301]
             3  Agents affecting metabolism
              39  Other agents affecting metabolism
               399  Miscellaneous
                3999  Others
                 D11082  Anifrolumab (USAN); Anifrolumab (genetical recombination) (JAN)
            Target-based classification of drugs [BR:br08310]
             Cytokines and receptors
              Cytokine receptors
               Interferon receptors
                IFNAR1
                 D11082  Anifrolumab (USAN) &lt;JP/US&gt;
                IFNAR2
                 D11082  Anifrolumab (USAN) &lt;JP/US&gt;
            New drug approvals in the USA [br08319.html]
             New molecular entities and new therapeutic biological products
              D11082
            New drug approvals in Europe [br08329.html]
             European public assessment reports (EPAR) authorised medicine
              D11082
            New drug approvals in Japan [br08318.html]
             Drugs with new active ingredients
              D11082
            New drug approvals in the USA, Europe and Japan [br08328.html]
             Approval dates by FDA, EMA and PMDA
              D11082
DBLINKS     CAS: 1326232-46-5
            PubChem: 375581029
///
